MI PHARMACY LIMITED 30/09/2023 iXBRL

MI PHARMACY LIMITED 30/09/2023 iXBRL

MI PHARMACY LIMITED - Company Information

Print Friendly Version

33 30/09/2023 2023-09-30 false false false false false false false false false false true false false true false false false false false false false No description of principal activities is disclosed 2022-10-01 Sage Accounts Production 21.0 - FRS102_2021 xbrli:pure xbrli:shares iso4217:GBP 7694589 2022-10-01 2023-09-30 7694589 2023-09-30 7694589 2022-09-30 7694589 2021-10-01 2022-09-30 7694589 2022-09-30 7694589 2021-09-30 7694589 core:NetGoodwill 2022-10-01 2023-09-30 7694589 core:PlantMachinery 2022-10-01 2023-09-30 7694589 core:FurnitureFittingsToolsEquipment 2022-10-01 2023-09-30 7694589 bus:RegisteredOffice 2022-10-01 2023-09-30 7694589 bus:LeadAgentIfApplicable 2022-10-01 2023-09-30 7694589 bus:Director1 2022-10-01 2023-09-30 7694589 bus:Director2 2022-10-01 2023-09-30 7694589 core:NetGoodwill 2022-09-30 7694589 core:NetGoodwill 2023-09-30 7694589 core:LandBuildings core:LongLeaseholdAssets 2022-09-30 7694589 core:FurnitureFittingsToolsEquipment 2022-09-30 7694589 core:MotorVehicles 2022-09-30 7694589 core:LandBuildings core:LongLeaseholdAssets 2023-09-30 7694589 core:FurnitureFittingsToolsEquipment 2023-09-30 7694589 core:MotorVehicles 2023-09-30 7694589 core:WithinOneYear 2023-09-30 7694589 core:WithinOneYear 2022-09-30 7694589 core:AfterOneYear 2023-09-30 7694589 core:AfterOneYear 2022-09-30 7694589 core:ShareCapital 2023-09-30 7694589 core:ShareCapital 2022-09-30 7694589 core:SharePremium 2023-09-30 7694589 core:SharePremium 2022-09-30 7694589 core:RetainedEarningsAccumulatedLosses 2023-09-30 7694589 core:RetainedEarningsAccumulatedLosses 2022-09-30 7694589 core:MoreThanFiveYears 2023-09-30 7694589 core:MoreThanFiveYears 2022-09-30 7694589 core:LandBuildings core:LongLeaseholdAssets 2022-10-01 2023-09-30 7694589 core:MotorVehicles 2022-10-01 2023-09-30 7694589 core:NetGoodwill 2022-09-30 7694589 core:CostValuation core:Non-currentFinancialInstruments 2022-09-30 7694589 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2023-09-30 7694589 core:CostValuation core:Non-currentFinancialInstruments 2023-09-30 7694589 core:Non-currentFinancialInstruments 2023-09-30 7694589 core:Non-currentFinancialInstruments 2022-09-30 7694589 core:LandBuildings core:LongLeaseholdAssets 2022-09-30 7694589 core:FurnitureFittingsToolsEquipment 2022-09-30 7694589 core:MotorVehicles 2022-09-30 7694589 core:LeasedAssetsHeldAsLessee core:MotorVehicles 2023-09-30 7694589 core:LeasedAssetsHeldAsLessee core:MotorVehicles 2022-09-30 7694589 bus:Director1 2022-09-30 7694589 bus:Director1 2023-09-30 7694589 bus:Director2 2022-09-30 7694589 bus:Director2 2023-09-30 7694589 bus:Director1 2021-09-30 7694589 bus:Director1 2022-09-30 7694589 bus:Director2 2021-09-30 7694589 bus:Director2 2022-09-30 7694589 bus:Director1 2021-10-01 2022-09-30 7694589 bus:Director2 2021-10-01 2022-09-30 7694589 bus:SmallEntities 2022-10-01 2023-09-30 7694589 bus:AuditExemptWithAccountantsReport 2022-10-01 2023-09-30 7694589 bus:FullAccounts 2022-10-01 2023-09-30 7694589 bus:SmallCompaniesRegimeForAccounts 2022-10-01 2023-09-30 7694589 bus:PrivateLimitedCompanyLtd 2022-10-01 2023-09-30
Company registration number: 7694589
MI PHARMACY LIMITED
Unaudited filleted financial statements
30 September 2023
MI PHARMACY LIMITED
Contents
Directors and other information
Accountants report
Statement of financial position
Notes to the financial statements
MI PHARMACY LIMITED
Directors and other information
Directors Mr Murtuza Broachwalla
Mrs Batul Murtuza
Company number 7694589
Registered office 216 Melton Road
Leicester
LE4 7PG
Business address 170 Park Road
Peterborough
PE1 2UF
Accountants SPK Shah & Co Ltd
Chartered Accountants &
Chartered Tax Advisers
216 Melton Road
Leicester
LE4 7PG
Bankers Santander UK plc
Bootle
Merseyside
L30 4GB
MI PHARMACY LIMITED
Chartered accountants report to the board of directors on the preparation of the
unaudited statutory financial statements of MI PHARMACY LIMITED
Year ended 30 September 2023
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of MI PHARMACY LIMITED for the year ended 30 September 2023 which comprise the statement of financial position and related notes from the company's accounting records and from information and explanations you have given us.
As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at http://www.icaew.com /en/members/regulations-standards-and-guidance/.
This report is made solely to the board of directors of MI PHARMACY LIMITED, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of MI PHARMACY LIMITED and state those matters that we have agreed to state to the board of directors of MI PHARMACY LIMITED as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than MI PHARMACY LIMITED and its board of directors as a body for our work or for this report.
It is your duty to ensure that MI PHARMACY LIMITED has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of MI PHARMACY LIMITED. You consider that MI PHARMACY LIMITED is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the financial statements of MI PHARMACY LIMITED. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.
SPK Shah & Co Ltd
Chartered Accountants &
Chartered Tax Advisers
216 Melton Road
Leicester
LE4 7PG
14 June 2024
MI PHARMACY LIMITED
Statement of financial position
30 September 2023
2023 2022
Note £ £ £ £
Fixed assets
Intangible assets 5 408,932 460,048
Tangible assets 6 330,126 320,512
Investments 7 110 50
_______ _______
739,168 780,610
Current assets
Stocks 115,336 117,203
Debtors 8 1,124,722 1,359,237
Cash at bank and in hand 128,757 85,992
_______ _______
1,368,815 1,562,432
Creditors: amounts falling due
within one year 9 ( 897,992) ( 718,900)
_______ _______
Net current assets 470,823 843,532
_______ _______
Total assets less current liabilities 1,209,991 1,624,142
Creditors: amounts falling due
after more than one year 10 ( 449,120) ( 585,575)
Provisions for liabilities ( 45,100) ( 46,735)
_______ _______
Net assets 715,771 991,832
_______ _______
Capital and reserves
Called up share capital 1,000 1,000
Share premium account 692,458 692,458
Profit and loss account 22,313 298,374
_______ _______
Shareholders funds 715,771 991,832
_______ _______
For the year ending 30 September 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
These financial statements were approved by the board of directors and authorised for issue on 14 June 2024 , and are signed on behalf of the board by:
Mr Murtuza Broachwalla
Director
Company registration number: 7694589
MI PHARMACY LIMITED
Notes to the financial statements
Year ended 30 September 2023
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 216 Melton Road, Leicester, LE4 7PG.
2. Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Turnover
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Operating leases
Lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.
Goodwill
Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business. Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed ten years.
Amortisation
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:
Goodwill - 5 % straight line
If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.
Tangible assets
tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Plant and machinery - 20 % straight line
Fittings fixtures and equipment - 20 % straight line
If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.
Fixed asset investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses. Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.
Provisions
Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event; it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense. Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised in finance costs in profit or loss in the period it arises.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 33 (2022: 41 ).
5. Intangible assets
Goodwill Total
£ £
Cost
At 1 October 2022 and 30 September 2023 1,022,329 1,022,329
_______ _______
Amortisation
At 1 October 2022 562,281 562,281
Charge for the year 51,116 51,116
_______ _______
At 30 September 2023 613,397 613,397
_______ _______
Carrying amount
At 30 September 2023 408,932 408,932
_______ _______
At 30 September 2022 460,048 460,048
_______ _______
6. Tangible assets
Long leasehold property Fixtures, fittings and equipment Motor vehicles Total
£ £ £ £
Cost
At 1 October 2022 63,100 146,472 262,810 472,382
Additions 27,828 55,466 - 83,294
_______ _______ _______ _______
At 30 September 2023 90,928 201,938 262,810 555,676
_______ _______ _______ _______
Depreciation
At 1 October 2022 1,055 104,667 46,146 151,868
Charge for the year 7,370 13,750 52,562 73,682
_______ _______ _______ _______
At 30 September 2023 8,425 118,417 98,708 225,550
_______ _______ _______ _______
Carrying amount
At 30 September 2023 82,503 83,521 164,102 330,126
_______ _______ _______ _______
At 30 September 2022 62,045 41,805 216,664 320,514
_______ _______ _______ _______
Obligations under finance leases
Included within the carrying value of tangible assets are the following amounts relating to assets held under finance leases or hire purchase agreements:
Motor vehicles
£
At 30 September 2023 125,809
_______
At 30 September 2022 162,876
_______
7. Investments
Shares in group undertakings and participating interests Total
£ £
Cost
At 1 October 2022 50 50
Additions 60 60
_______ _______
At 30 September 2023 110 110
_______ _______
Impairment
At 1 October 2022 and 30 September 2023 - -
_______ _______
Carrying amount
At 30 September 2023 110 110
_______ _______
At 30 September 2022 50 50
_______ _______
8. Debtors
2023 2022
£ £
Trade debtors 367,716 359,799
Other debtors 757,006 999,438
_______ _______
1,124,722 1,359,237
_______ _______
9. Creditors: amounts falling due within one year
2023 2022
£ £
Bank loans and overdrafts 75,368 27,399
Trade creditors 618,914 487,197
Corporation tax, social security and other taxes 4,281 58,356
Other creditors 199,429 145,948
_______ _______
897,992 718,900
_______ _______
10. Creditors: amounts falling due after more than one year
2023 2022
£ £
Bank loans and overdrafts 340,937 458,962
Other creditors 108,183 126,613
_______ _______
449,120 585,575
_______ _______
11. Operating leases
The company as lessee
The total future minimum lease payments under non-cancellable operating leases are as follows:
£ £
Later than 5 years 294,820 401,893
_______ _______
12. Directors advances, credits and guarantees
During the year the directors entered into the following advances and credits with the company:
2023
Balance brought forward Advances /(credits) to the directors Amounts repaid Balance o/standing
£ £ £ £
Mr Murtuza Broachwalla 120,275 78,159 ( 120,275) 78,159
Mrs Batul Murtuza 120,275 78,159 (120,275) 78,159
_______ _______ _______ _______
240,550 156,318 ( 240,550) 156,318
_______ _______ _______ _______
2022
Balance brought forward Advances /(credits) to the directors Amounts repaid Balance o/standing
£ £ £ £
Mr Murtuza Broachwalla 63,996 120,275 ( 63,996) 120,275
Mrs Batul Murtuza 63,996 120,275 ( 63,996) 120,275
_______ _______ _______ _______
127,992 240,550 ( 127,992) 240,550
_______ _______ _______ _______
13. Controlling party
The company is controlled by the directors by virtue of their ownership of 100% of the issued share capital.